TD Cowen analyst Tyler Van Buren has maintained their bullish stance on CGON stock, giving a Buy rating on November 14.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight CG Oncology, Inc.’s promising future. The company has initiated a rolling Biologics License Application (BLA) submission for its product, creto, which is expected to be completed by 2026. This step is crucial as it positions creto for potential accelerated approval, supported by its Breakthrough and Fast Track designations. The successful approval of similar treatments, such as JNJ’s Inlexzo, further boosts confidence in creto’s regulatory path.
Moreover, CG Oncology’s strategic enhancements to creto, including streamlined administration and improved storage conditions, are expected to differentiate it in the market. The anticipated efficacy metrics, such as duration of response and complete response rate, are projected to exceed 12 months, adding to its appeal. The recent approval of single-arm trials by the FDA for similar treatments reduces the regulatory risk for creto, suggesting a favorable outlook for CG Oncology’s stock performance.
In another report released on November 14, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.
CGON’s price has also changed dramatically for the past six months – from $24.170 to $41.010, which is a 69.67% increase.